Table 3.
Comparative features and advantages of therapeutic MAbs generated in different animals.
| Mouse | Rabbit | Camelid | Chicken | |
|---|---|---|---|---|
| Evolutionary distance from humans, years8 |
91 million |
91 million |
92 million |
310 million |
| Animal host class |
mammalia |
mammalia |
mammalia |
aves |
| Robust immune response against conserved proteins |
- |
- |
- |
+ |
| Cross-reactive MAbs for preclinical models |
- |
+/- |
+/- |
+ |
| Canonical IgG |
+ |
+ |
+ |
+ |
| HCDR3 length (aa)* |
9.1±2.0 36 |
12.8±3.6 36 |
14.5±3.7 58 |
15.9±2.8 36 |
| Long paratope with average HCDR3 >14 aa |
- |
- |
+ |
+ |
| Nanobodies from host |
- |
- |
+ |
- |
| Immunization costs and animal logistics |
$ |
$ |
$$$ |
$ |
| Access to humanized animals |
+ |
- |
- |
+ |
| Diverse accessible B cell repertoire (spleen, marrow) | + | + | - | + |
*Kabat numbering scheme used throughout paper. Any literature comparisons using alternate numbering schemes have been converted to Kabat. Camelid HCDR3 length is based on Llama VHH.